Australian nuclear medicine company Telix Pharmaceuticals has reported a 726 per cent rise in revenue for the six months to the end of June.
The company reported revenue of $24.047 million for the period, up from $2.91 million for the corresponding period in 2021.
The growth was driven by the US commercial launch of Illuccix. It is a positron emission tomography (PET) agent for the diagnostic imaging of men with prostate cancer. It is also approved in Australia
Revenue for the period was dominated by $19.3 million from the US. The company reported a $70.6 million loss for the period, which it attributed to costs associated with the commercial launch of Illuccix.
The company reported $122 million in cash at the end of June.